Literature DB >> 27817023

Analysis of binding centers in nicotinic receptors with the aid of synthetic peptides.

I E Kasheverov1, E V Kryukova2, D S Kudryavtsev1, I A Ivanov1, N V Egorova1, M N Zhmak1, E N Spirova1, I V Shelukhina1, A V Odinokov3, M V Alfimov3, V I Tsetlin1.   

Abstract

We studies the receptor-binding specificity of the synthetic peptide HAP (High Affinity Peptide) and its analogues, which are regarded as a model of the orthosteric site nicotinic acetylcholine receptors (nAChR). Using radioligand analysis, electrophysiology tests, and calcium imaging, we assessed the ability of HAP to interact with nAChR antagonists: long α-neurotoxins and α-conotoxins. A high affinity of HAP for α-bungarotoxin and the absence of its interaction with α-cobratoxin and α-conotoxins was found. The synthesized analogues of HAP in general retained the properties of the original peptide. Thus, HAP cannot be a model of a ligand-binding site.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27817023     DOI: 10.1134/S1607672916050070

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  15 in total

1.  The binding site of acetylcholine receptor as visualized in the X-Ray structure of a complex between alpha-bungarotoxin and a mimotope peptide.

Authors:  M Harel; R Kasher; A Nicolas; J M Guss; M Balass; M Fridkin; A B Smit; K Brejc; T K Sixma; E Katchalski-Katzir; J L Sussman; S Fuchs
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

2.  Imaging of receptor trafficking by using alpha-bungarotoxin-binding-site-tagged receptors.

Authors:  Yoko Sekine-Aizawa; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

Review 3.  Naturally occurring and synthetic peptides acting on nicotinic acetylcholine receptors.

Authors:  Igor E Kasheverov; Yuri N Utkin; Victor I Tsetlin
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  Rational design of new ligands for nicotinic receptors on the basis of α-conotoxin PnIA.

Authors:  I E Kasheverov; D S Kudryavtsev; I A Ivanov; M N Zhmak; A O Chugunov; V M Tabakmakher; E A Zelepuga; R G Efremov; V I Tsetlin
Journal:  Dokl Biochem Biophys       Date:  2015-05-05       Impact factor: 0.788

Review 5.  The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily.

Authors:  Jean-Pierre Changeux
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

6.  Expression of the alpha-bungarotoxin binding site of the nicotinic acetylcholine receptor by Escherichia coli transformants.

Authors:  J M Gershoni
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

7.  Distribution of alpha-bungarotoxin binding sites over residues 173-204 of the alpha subunit of the acetylcholine receptor.

Authors:  P T Wilson; E Hawrot; T L Lentz
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

Review 8.  Three-finger snake neurotoxins and Ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and endogenous modulators.

Authors:  Victor I Tsetlin
Journal:  Trends Pharmacol Sci       Date:  2014-12-17       Impact factor: 14.819

9.  Differential binding of nicotine and alpha-bungarotoxin to residues 173-204 of the nicotinic acetylcholine receptor alpha 1 subunit.

Authors:  T L Lentz
Journal:  Biochemistry       Date:  1995-01-31       Impact factor: 3.162

10.  6-bromohypaphorine from marine nudibranch mollusk Hermissenda crassicornis is an agonist of human α7 nicotinic acetylcholine receptor.

Authors:  Igor E Kasheverov; Irina V Shelukhina; Denis S Kudryavtsev; Tatyana N Makarieva; Ekaterina N Spirova; Alla G Guzii; Valentin A Stonik; Victor I Tsetlin
Journal:  Mar Drugs       Date:  2015-03-12       Impact factor: 5.118

View more
  1 in total

Review 1.  Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment.

Authors:  Wuyi Liu; Ming D Li
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.